Molecular mechanisms of LRRK1 regulation of bone homeostasis
Active Project Grant Awarded Last action
- Award ID
- R01AR078843
- Recipient
-
Loma Linda Veterans Association For Research And Education UEI Y1N6M64MZPQ8
- Awarding agency
-
National Insititue of Arthritis and Musculoskeletal and Skin Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $4,015,858
Award facts
- Assistance listing
- 93.846 Arthritis, Musculoskeletal and Skin Diseases Research
- Completion date 96% complete
- Originally
- Place of performance
- Loma Linda, CA 92357, USA
Award details come from USAspending.gov.
Description
- Abstract
- Leucine rich repeat kinase 1 (LRRK1), a novel serine/threonine kinase, is expressed in bones, brain and other tissues. We recently demonstrated that LRRK1 gene knockout (KO) mice as well as a patient with a LRRK1 gene mutation are severely osteopetrotic due to osteoclast dysfunction and reduced bone resorption in long and vertebra bones. More importantly, LRRK1 KO mice had lifelong bone accumulation and responded normally to the anabolic actions of teriparatide treatment but were resistant to ovariectomy (OVX)-induced bone boss. These observations make LRRK1 an ideal target of a novel anti-resorption drugs for treatment of osteoporosis. In this grant, our focus is to perform in vivo and in vitro studies to study the role of LRRK1-mediated phosphorylation of osteopetrosis specific transmembrane protein 1 (OSTM1) in the regulation of chloride channel 7 (CLC7) complex stabilization, lysosomal peripheral movement, lysosomal acid secretion and OC function. To this end, we hypothesize that LRRK1 phosphorylation of OSTM1 at residues of threonine 328 and serine 329 regulates OC function and bone resorption by stabilization of OSTM1/CLC7 complex and promotion of lysosomal peripheral movement and lysosomal acid secretion into lacuna in vivo. Four-year studies proposed in this grant will deliver the role of LRRK1 phosphorylation of threonine and serine residues of OSTM1 in regulation of bone resorption in vitro and in vivo. The results of this application will help our understanding of molecular mechanisms of LRRK1 and OSTM1 actions in osteoclast and develop potential inhibitors of LRRK1 for treatment of osteoporosis in future.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $16,115 | |
| Amendment | $290,070 | |
| Amendment | $290,070 | |
| Amendment | $0 | |
| Amendment | $0 | |
| Amendment | $22,561 | |
| Amendment | $22,561 | |
| Amendment | $22,561 | |
| Amendment | $290,070 | |
| Amendment | $290,070 | |
| Amendment | $290,070 | |
| Amendment | $290,070 | |
| Amendment | $32,230 | |
| Amendment | $32,230 | |
| Amendment | $32,230 | |
| Amendment | $290,070 | |
| Amendment | $290,070 | |
| Amendment | $290,070 | |
| Amendment | $290,070 | |
| Amendment | $290,070 | |
| Amendment | $322,300 | |
| Original award | $322,300 |
Show all 22
Quick answers
Who received award R01AR078843?
R01AR078843 was awarded to Loma Linda Veterans Association For Research And Education by National Insititue of Arthritis and Musculoskeletal and Skin Diseases (National Institutes of Health) on January 1, 2022.
How much is award R01AR078843 worth?
$4,015,858 has been obligated on R01AR078843.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award